T-cell Receptor (TCR) targeting with Multivalent T-cell Engagers
Debasmita PauliD, Abhishek Kulkarni, Freddys F. RodrigueziD, Declan Dahlberg, Lakmal Rozumalski, Carston R. WagneriD
Abstract
T-cell engagers (TCEs) for cancer immunotherapy have traditionally relied on high affinity single chain fragment variable (scFv) domains to target CD3, specifically the {varepsilon} chain, for the activation of T-cells. Despite their clinical success, there have been reports of TCEs driving systemic toxicity, non-specific T-cell activation, on-target off-tumor effects, and severe inflammation due to cytokine release. To address these limitations, we designed multivalent TCEs using Chemically Self-Assembled Nanorings (CSANs) that target the /{beta} constant region of the T-cell receptor (TCR) in the TCR/CD3 complex using a moderate affinity TCR nanobody (TCRVHH). Nanobodies offer superior physical and chemical properties over scFvs-including higher solubility, stability and lower production cost-making them increasingly popular as structural units of TCEs. We compared the efficacy and safety profile of this moderate affinity, nanobody-based TCR binder against high affinity CD3scFv based CSANs across EGFR and PSMA expressing solid tumor models. While the CD3scFv CSANs offered potent cytotoxicity, they also induced antigen independent T-cell activation bypassing the requirement of tumor crosslinking for cytotoxicity. In contrast the TCRVHH CSANs required strict antigen engagement to trigger cytotoxicity, significantly reducing non-specific T-cell activation and thus enhancing the safety profile. Although the initiation of cytotoxicity was kinetically slower than the CD3scFv counterpart, TCRVHH CSANs achieved comparable end point cytotoxicity across multiple antigen densities, as well as in 3D tumor spheroids. Through this study we demonstrate the applicability of nanobodies as T-cell targeting domains, enhanced specificity and safety of moderate affinity T-cells binders and the diversification of T-cell targeting epitopes without compromising the efficacy of TCEs. Abstract Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=96 SRC="FIGDIR/small/725710v2_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@9bcb83org.highwire.dtl.DTLVardef@4e30daorg.highwire.dtl.DTLVardef@1695931org.highwire.dtl.DTLVardef@15ec7ab_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multivalent Tri-Functional T-cell Engagers by Chemically Induced Protein Self-Assembly
Declan Dahlberg, Brandi McKnight, … Carston R. Wagner·bioRxiv·Jul 29, 2025
- Tuning T-cell immunological synapse by modular DNA-Nanobody engagers for precision immunotherapy
Juliette Prothon, Gaurav Verma, … Patrick Chames·bioRxiv·Jul 23, 2026
- Targeting human γδ T cells as a potent and safe alternative to pan-T cells bispecific cell engagers
- TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation
T. Peters, V. Muehlgrabner, … J. B. Huppa·bioRxiv·Mar 16, 2023
- Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity
- Catch-bond engineering surpasses high-affinity maturation for T cell receptor therapies against solid tumors
Tianqi Huang, Runyu Wang, … Xiang Zhao·bioRxiv·Jul 29, 2026